Patients who have genomic tumor aberrations, such as EGFR or ALK, and are receiving an approved EGFR- or ALK-directed therapy should have disease progression prior to receiving nivolumab (Bristol-Myers Squibb, 2016; Rizvi et al., 2015). The gene discussed is ALK; the disease is neoplasm.